Biotechnology and its Applications

The chapter is organised around the four numbered sections of NCERT Chapter 10. 10.1 Biotechnological applications in agriculture opens with tissue culture — totipotency, micropropagation, meristem culture for virus-free plants, and somatic hybridisation (the pomato) — before turning to genetically modified crops: what GM has achieved in general, and then the two flagship Indian case studies, Bt cotton (a toxin activated only in the insect gut) and RNAi-protected tobacco (silencing a nematode's own mRNA). 10.2 Biotechnological applications in medicine covers genetically engineered human insulin (the Eli Lilly two-chain strategy), gene therapy (the ADA deficiency story), and molecular diagnosis by PCR and ELISA. 10.3 Transgenic animals surveys the four reasons animals are genetically engineered, anchored by the transgenic cow Rosie. 10.4 Ethical issues closes with the GEAC as India's regulatory body and biopiracy, worked through the Basmati rice patent dispute. Two derivations trace the Bt toxin's activation mechanism step by step and the RNAi silencing pathway used against the nematode; a third traces the cloning-and-expression pipeline for producing a human protein such as insulin in a bacterium. Worked examples combine NCERT-style reasoning questions with a NEET-style assertion-reason item.

Tissue culture: totipotency, micropropagation and meristem culture

The starting point of plant biotechnology in agriculture is a cell-biological property rather than a genetic-engineering trick. During the 1950s scientists learned that a whole plant could be regenerated from an explant — any part of a plant taken out and grown in a test tube under sterile conditions on a special nutrient medium. This capacity of a single cell or explant to give rise to an entire plant is called totipotency. The nutrient medium must supply a carbon source (typically sucrose), inorganic salts, vitamins, amino acids and growth regulators such as auxins and cytokinins. Exploiting totipotency to produce thousands of genetically identical plants in a very short time is called micropropagation. Because every plant produced this way descends clonally from the same original cell, they are genetically identical to the source plant and to each other — such clones are called somaclones. Tomato, banana and apple are cited as important food plants already produced commercially by this method. A second, medically important application of tissue culture is the recovery of healthy plants from diseased stock. Even when a whole plant is infected by a virus, its meristem — apical and axillary — remains free of virus. Removing the meristem and growing it in vitro therefore yields virus-free plants; scientists have successfully cultured meristems of banana, sugarcane and potato this way. A further extension is somatic hybridisation. Scientists isolate single plant cells and digest away their cell walls to obtain naked protoplasts (cells bounded only by the plasma membrane). Protoplasts from two different varieties, each carrying a desirable trait, can be fused to form a hybrid protoplast, which is then grown into a new hybrid plant — these are somatic hybrids, and the process is somatic hybridisation. The chapter's own example is the fusion of a tomato protoplast with a potato protoplast to produce pomato; the plant combined characteristics of both parents but did not have the full combination of traits needed for commercial use.

Genetically modified crops: what GM achieves, and Bt cotton

Three broad routes exist for increasing food production: agro-chemical based agriculture, organic agriculture, and genetically engineered crop-based agriculture. The Green Revolution tripled food supply mainly through improved management practices and heavy use of agrochemicals (fertilisers and pesticides), but agrochemicals are often too expensive for farmers in the developing world, and conventional breeding alone cannot keep pace with demand. This is the practical case for Genetically Modified Organisms (GMOs) — plants, bacteria, fungi and animals whose genes have been deliberately altered by manipulation, generally via recombinant DNA technology. Genetic modification of crops has: made crops more tolerant of abiotic stresses (cold, drought, salt, heat); reduced reliance on chemical pesticides through pest-resistant crops; helped reduce post-harvest losses; increased the efficiency of mineral usage, preventing early exhaustion of soil fertility; and enhanced nutritional value, the flagship example being golden rice, engineered to be enriched in Vitamin A. GM crops are also used to create tailor-made plants supplying industries with alternative starches, fuels and pharmaceuticals. The chapter's central pest-resistance case study is Bt cotton. Certain strains of the soil bacterium Bacillus thuringiensis (Bt) produce crystal proteins toxic to specific insect orders: lepidopterans (tobacco budworm, armyworm), coleopterans (beetles) and dipterans (flies, mosquitoes). These crystal proteins exist inside the bacterium as inactive protoxins, which is precisely why the toxin does not kill the Bacillus that makes it. Scientists isolated the specific Bt toxin genes from B. thuringiensis and incorporated them into crop plants such as cotton, corn, rice, tomato, potato and soyabean. The gene choice depends on the crop and the targeted pest, since most Bt toxins are insect-group specific: the proteins encoded by cryIAc and cryIIAb control cotton bollworms, while cryIAb controls corn borer.

RNA interference: silencing the nematode's own genes

The chapter's second pest-resistance case study protects tobacco roots not with a toxin but by hijacking a natural cellular defence mechanism. The nematode Meloidogyne incognitia infects tobacco roots, causing serious yield reduction. The protective strategy exploits RNA interference (RNAi), a method of cellular defence present in all eukaryotic organisms, that silences a specific mRNA through a complementary double-stranded RNA (dsRNA) molecule that binds it and prevents its translation. Naturally, such complementary RNA can originate from viral infections with RNA genomes or from mobile genetic elements (transposons) that replicate through an RNA intermediate. Using Agrobacterium vectors, scientists introduced nematode-specific genes into the host tobacco plant in a way engineered to produce both sense and anti-sense RNA inside the host cells. Being complementary to each other, these two RNA strands form dsRNA within the plant, which triggers RNAi and silences the specific mRNA of the invading nematode — not a plant gene, the parasite's own gene. Consequently the nematode cannot survive in a transgenic host expressing this interfering RNA, and the transgenic plant is protected from infestation.

Genetically engineered human insulin

Managing adult-onset diabetes needs insulin at regular intervals. Before recombinant DNA technology, insulin was extracted from the pancreas of slaughtered cattle and pigs; being a foreign protein, animal-source insulin caused allergies or other reactions in some patients. Human insulin, chemically, consists of two short polypeptide chains — chain A and chain B — linked together by disulphide bridges. In mammals, insulin is synthesised as a pro-hormone, analogous to a pro-enzyme, carrying an extra stretch called the C peptide. The C peptide is absent from mature insulin and is removed during the pro-hormone's maturation. The central challenge for producing insulin via rDNA technology was therefore not making the chains but assembling them into the correctly folded mature form. In 1983, the American company Eli Lilly prepared two separate DNA sequences corresponding to the human insulin A and B chains and introduced them into plasmids of E. coli, so the two chains were produced separately. The chains were then extracted and combined by creating disulphide bonds to form functional human insulin — bypassing the need to replicate the natural C-peptide-mediated folding pathway inside the bacterium. Because this insulin is molecularly identical to the human hormone, it does not provoke the immune reactions associated with the older animal-derived product.

Gene therapy and molecular diagnosis

Gene therapy is a collection of methods that corrects a gene defect diagnosed in a child or embryo, by inserting genes into a person's cells and tissues to treat disease. Correction of a genetic defect involves delivering a normal gene into the individual (or embryo) to take over the function of, and compensate for, the non-functional gene. The chapter's landmark case is adenosine deaminase (ADA) deficiency, treated with the first-ever clinical gene therapy in 1990, given to a four-year-old girl. ADA is an enzyme crucial to immune system function; the disorder arises from deletion of the gene encoding it. Two existing (non-curative) treatments were bone marrow transplantation and enzyme replacement therapy (injecting functional ADA). As a first step toward gene therapy, lymphocytes from the patient's blood are grown in culture outside the body; a functional ADA cDNA is introduced into these lymphocytes using a retroviral vector, and the engineered lymphocytes are returned to the patient. Because these lymphocytes are not immortal cells, the patient requires periodic infusion of fresh genetically engineered lymphocytes. A permanent cure would instead require introducing the isolated gene into cells at early embryonic stages.

Molecular diagnosis exploits recombinant DNA technology, PCR and ELISA for early detection of disease, which conventional serum/urine analysis often cannot achieve until the pathogen concentration is already high. PCR (Polymerase Chain Reaction) amplifies a pathogen's nucleic acid so that even very low, pre-symptomatic concentrations of bacteria or virus can be detected — it is used routinely to detect HIV in suspected AIDS patients and to detect mutated genes in suspected cancer patients, as well as other genetic disorders. A related technique uses a single-stranded DNA or RNA probe tagged with a radioactive molecule, hybridised to its complementary DNA in a clone of cells and detected by autoradiography; a clone carrying the mutated gene fails to show up, since the probe lacks complementarity to it. ELISA (Enzyme Linked Immuno-Sorbent Assay) works on the principle of antigen-antibody interaction, detecting infection either through the presence of pathogen antigens (proteins, glycoproteins) or through antibodies the body has raised against the pathogen.

Transgenic animals

Animals whose DNA has been manipulated to carry and express an extra, foreign gene are called transgenic animals. Transgenic rats, rabbits, pigs, sheep, cows and fish have all been produced, but over 95% of all existing transgenic animals are mice. Four reasons drive their production. Normal physiology and development — transgenic animals let researchers study how genes are regulated and how they affect normal body function and development; introducing genes from other species that alter formation of a factor such as insulin-like growth factor, and studying the resulting biological effects, reveals that factor's normal biological role. Study of disease — transgenic animals designed as models for human diseases (cancer, cystic fibrosis, rheumatoid arthritis, Alzheimer's) let researchers investigate new treatments. Biological products — medicines needing biological products that are otherwise expensive can be produced by introducing the DNA/gene coding for that product; an example is the human protein alpha-1-antitrypsin used to treat emphysema, with similar approaches attempted for phenylketonuria (PKU) and cystic fibrosis. In 1997 the first transgenic cow, Rosie, produced human protein-enriched milk (2.4 grams per litre) containing human alpha-lactalbumin, nutritionally more balanced for human babies than natural cow milk. Vaccine safety — transgenic mice are being developed to test vaccine safety (e.g. polio vaccine) before human use, potentially replacing monkeys for this purpose. Chemical safety testing (toxicity testing) — transgenic animals carrying genes that make them more sensitive to toxic substances are exposed to the substance under study and the effects observed, yielding faster toxicity results than conventional testing.

Ethical issues: GEAC and biopiracy

Manipulation of living organisms by humans cannot proceed unregulated, both on moral grounds and because genetic modification can have unpredictable ecological results once GM organisms are released into an ecosystem. The Indian Government therefore established the Genetic Engineering Approval Committee (GEAC), the body responsible for deciding the validity of GM research and the safety of introducing GM organisms for public use. A second ethical concern is patents granted over living organisms and traditional bio-resources. There is growing public objection to companies obtaining patents on products and technologies using genetic material, plants and biological resources that farmers and indigenous communities have long identified, developed and used. The chapter's worked example is rice: India alone has an estimated 200,000 rice varieties, with 27 documented Basmati varieties distinguished by their unique aroma and flavour, referenced in ancient texts, folklore and poetry for centuries. In 1997, an American company obtained US patent rights on a Basmati rice variety, allowing it to sell this "new" variety, actually derived by crossing Indian farmers' Basmati with semi-dwarf varieties, as its own invention; the patent's claimed functional equivalents could have restricted others selling Basmati rice. Similar attempts have targeted Indian traditional herbal medicine uses, e.g. turmeric and neem.

Biopiracy is the term for such use of a country's bio-resources by multinational companies and other organisations without proper authorisation from, or compensation to, the country and people concerned. Industrialised nations tend to be financially rich but biodiversity-poor, while developing and underdeveloped nations are rich in biodiversity and traditional knowledge — a mismatch that has produced a growing recognition of the injustice of inadequate compensation and benefit-sharing. In response, the Indian Parliament cleared a second amendment of the Indian Patents Bill addressing such issues, including patent terms, emergency provisions, and research and development initiatives.

Board level - Which part of the plant is best suited for making virus-free plants, and why

Step 1. Recall the relevant fact from tissue culture: even when a whole plant is infected by a virus, its meristem (apical and axillary) remains free of virus, unlike the rest of the infected plant tissue.

Step 2. Connect this to totipotency. Because a meristematic cell retains the capacity to regenerate an entire plant (totipotency) when cultured in vitro on an appropriate nutrient medium, a virus-free meristem can, by itself, be grown into a complete, virus-free plant.

Step 3. State why no other tissue works as well. Other tissues of an infected plant carry the virus throughout, so culturing them would simply propagate infected clones; only the meristem is naturally shielded from viral spread within the plant body.

Step 4. Conclude with the applied result. The meristem (apical and axillary) is the tissue of choice for producing virus-free plants, because it remains virus-free even in an infected plant; scientists have used this method to obtain virus-free banana, sugarcane and potato plants by culturing isolated meristems in vitro.

Board level - Compare and contrast the advantages and disadvantages of producing genetically modified crops

Step 1. List the advantages stated in the chapter. GM crops can be made more tolerant to abiotic stresses (cold, drought, salt, heat); they reduce reliance on chemical pesticides through built-in pest resistance (e.g. Bt cotton); they help reduce post-harvest losses; they increase the efficiency of mineral usage, preventing early exhaustion of soil fertility; and they can enhance nutritional value, as in Vitamin-A-enriched golden rice.

Step 2. Note the wider industrial advantage. GM technology can also create tailor-made plants supplying industries with alternative resources such as starches, fuels and pharmaceuticals, beyond direct food-crop benefits.

Step 3. State the disadvantages/concerns the chapter raises. Genetic modification of organisms can have unpredictable results when such organisms are released into an ecosystem, which is exactly why regulatory oversight (GEAC) exists; the chapter also flags that a technology developed from a farming community's traditional varieties (as with Basmati) can be patented elsewhere without compensation, harming the very communities that developed the original genetic resource.

Step 4. Weigh the two sides for a balanced answer. GM crops offer real, demonstrated gains in yield stability, pesticide reduction and nutrition, but these gains carry ecological uncertainty on release and raise unresolved questions of regulation, patenting and benefit-sharing with the original resource-holders — which is why GM crop-based agriculture is presented alongside, not as an unconditional replacement for, regulated evaluation via bodies like the GEAC.

Competitive level (NEET) - Assertion-reason: Bt toxin and the bacterium's own safety

Assertion (A): Crystals of Bt toxin produced by Bacillus thuringiensis do not kill the bacterium itself. Reason (R): The Bt toxin protein exists as an inactive protoxin within the bacterium and is converted to its active form only by the alkaline pH of an insect's gut.

Step 1. Evaluate Assertion (A). The chapter states directly that Bt toxin crystals do not kill Bacillus thuringiensis itself. A is true.

Step 2. Evaluate Reason (R). The chapter explains that the Bt toxin protein exists as inactive protoxins, and is converted into an active toxin form only once an insect ingests it, because the alkaline pH of the insect gut solubilises the crystals and activates the toxin. R is true.

Step 3. Check whether R correctly explains A. Since the toxin is inactive inside the bacterium and only becomes active under the insect gut's alkaline conditions — conditions absent inside the bacterium's own body — R directly explains why A holds. R is a correct explanation of A.

Step 4. Select the final answer, and note the commonly mis-marked distractor. Students often select "bacteria are resistant to the toxin," which is factually wrong per the chapter (option a in the original NCERT exercise); the correct mechanism is inactivation, not resistance. A is true, R is true, and R is the correct explanation of A — the toxin is inactive protoxin inside the bacterium and is activated only by the alkaline gut environment of the target insect. Timing note: under 90 seconds. Assertion-reason items on this chapter almost always hinge on one precise mechanistic word (here, "inactive protoxin" versus "resistant") — recall the exact NCERT phrasing rather than a paraphrase, since NEET distractors are built from plausible-sounding but wrong paraphrases like "resistant" or "toxin is immature."

A frequent error is treating "genetically modified" and "transgenic" as always meaning animal or human genes have been inserted; in this chapter's actual examples the inserted genes are typically bacterial (Bt cry genes into cotton) or the plant's own gene sequences reconfigured (RNAi in tobacco using nematode-specific, not plant, genes), so students must check the actual source organism of the introduced gene rather than assuming a generic "foreign DNA" story. A second trap is confusing RNAi's target: the silenced mRNA in the tobacco-nematode example belongs to the nematode, not the tobacco plant — many students incorrectly write that the plant's own gene is silenced. A third trap is describing the Bt toxin as directly toxic to the bacterium producing it or as active immediately on ingestion; in fact it is inactive inside the bacterium and requires the insect gut's alkaline pH for activation, a two-step mechanism the exercises test explicitly. A fourth trap is conflating gene therapy's ADA-deficiency lymphocyte procedure with a permanent cure; the chapter is explicit that lymphocyte-based gene therapy is not permanent because lymphocytes are not immortal, and periodic reinfusion is required unless the corrective gene is introduced at the embryonic stage. Finally, students often forget that GEAC is specifically the Indian regulatory body for GM research and release safety, not a generic international body, and that biopiracy concerns uncompensated use of bio-resources and traditional knowledge, illustrated concretely by the Basmati rice patent case, not a general objection to biotechnology itself.

• Explain totipotency and describe how it underlies micropropagation, meristem culture for virus-free plants, and somatic hybridisation, using the pomato example
• State the two-step Bt toxin activation mechanism (inactive protoxin, activated by alkaline insect gut pH) and name at least two cry genes with their target pests
• Describe the RNAi mechanism used against Meloidogyne incognitia in transgenic tobacco, correctly identifying that the nematode's own mRNA is silenced
• Trace the Eli Lilly 1983 method for producing recombinant human insulin, including why the A and B chains are made separately
• Explain gene therapy using the ADA deficiency example, including why the original lymphocyte-based treatment was not permanent
• Distinguish PCR-based and ELISA-based molecular diagnosis and state what each detects
• List the four reasons transgenic animals (mostly mice) are produced, with the Rosie example for biological products
• Explain the role of the GEAC and define biopiracy using the Basmati rice patent case

Ask the tutor: Want to work through a few more NEET-style assertion-reason and mechanism questions on Bt toxin activation, RNAi silencing, and the ADA gene therapy pathway before you move on to Organisms and Populations?